Pfizer stock rises as FDA speeds HYMPAVZI review and TrumpRx discounts keep pricing in focus
NEW YORK, Feb 6, 2026, 14:23 EST — Regular session.
Pfizer shares climbed 72 cents, or 2.7%, to $27.22 in afternoon trading Friday, outpacing the SPDR S&P 500 ETF’s roughly 1.7% gain. Roughly 30 million Pfizer shares traded hands.
Pfizer announced that the U.S. Food and Drug Administration has granted Priority Review for its hemophilia drug HYMPAVZI (marstacimab), targeting an approval decision by the second quarter of 2026. This designation trims the usual FDA review period by around four months. The expanded label aims to include patients as young as 6 years old, particularly those with inhibitors that reduce the effectiveness of standard factor replacement therapy. 1
The stock has been in focus following…
